117 related articles for article (PubMed ID: 36649714)
1. Development of a high-performance liquid chromatography method for rapid radiochemical purity measurement of [
Ioppolo JA; Alvarez de Eulate E; Cullen DR; Mohamed S; Morandeau L
J Labelled Comp Radiopharm; 2023 Mar; 66(3):58-72. PubMed ID: 36649714
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of a GMP-Compliant High-Pressure Liquid Chromatography Method for the Determination of the Chemical and Radiochemical Purity of [
Katzschmann I; Marx H; Kopka K; Hennrich U
Pharmaceuticals (Basel); 2021 Feb; 14(3):. PubMed ID: 33669095
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a UV-Radio-HPLC method to assess chemical and radiochemical purity of [
Pehli Vanoglu H; Ocak M; Caglar-Andac S
Appl Radiat Isot; 2022 Dec; 190():110487. PubMed ID: 36195037
[TBL] [Abstract][Full Text] [Related]
5. Development and Validation of Analytical Methods for Radiochemical Purity of
Orhon P; Desruet MD; Piquemal M; De Leiris N; Djaileb L; Vuillez JP; Bedouch P; Leenhardt J
Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631349
[TBL] [Abstract][Full Text] [Related]
6. Development and Validation of a High-Pressure Liquid Chromatography Method for the Determination of Chemical Purity and Radiochemical Purity of a [
Migliari S; Sammartano A; Scarlattei M; Serreli G; Ghetti C; Cidda C; Baldari G; Ortenzia O; Ruffini L
ACS Omega; 2017 Oct; 2(10):7120-7126. PubMed ID: 29520394
[No Abstract] [Full Text] [Related]
7. In Vitro and In Vivo Characterization of an
Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
[TBL] [Abstract][Full Text] [Related]
8. A Specific HPLC Method to Determine Residual HEPES in [
Migliari S; Scarlattei M; Baldari G; Silva C; Ruffini L
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889351
[TBL] [Abstract][Full Text] [Related]
9. Detrimental impact of aqueous mobile phases on 18F-labelled radiopharmaceutical analysis
Laferriere-Holloway TS; Rios A; van Dam RM
Anal Methods; 2023 Jan; 15(3):377-387. PubMed ID: 36542448
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of
Rodnick ME; Sollert C; Stark D; Clark M; Katsifis A; Hockley BG; Parr DC; Frigell J; Henderson BD; Bruton L; Preshlock S; Abghari-Gerst M; Piert MR; Fulham MJ; Eberl S; Gagnon K; Scott PJH
Nat Protoc; 2022 Apr; 17(4):980-1003. PubMed ID: 35246649
[TBL] [Abstract][Full Text] [Related]
11. Validation of analytical HPLC with post-column injection as a method for rapid and precise quantification of radiochemical yields.
Humpert S; Hoffmann C; Neumaier F; Zlatopolskiy BD; Neumaier B
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Aug; 1228():123847. PubMed ID: 37634390
[TBL] [Abstract][Full Text] [Related]
12. Improved quality control of [
Kraihammer M; Garnuszek P; Bauman A; Maurin M; Alejandre Lafont M; Haubner R; von Guggenberg E; Gabriel M; Decristoforo C
EJNMMI Radiopharm Chem; 2023 Mar; 8(1):7. PubMed ID: 36971890
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
[TBL] [Abstract][Full Text] [Related]
14. Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [
Hooijman EL; Ntihabose CM; Reuvers TGA; Nonnekens J; Aalbersberg EA; van de Merbel JRJP; Huijmans JE; Koolen SLW; Hendrikx JJMA; de Blois E
EJNMMI Radiopharm Chem; 2022 Nov; 7(1):29. PubMed ID: 36333648
[TBL] [Abstract][Full Text] [Related]
15. Validation of HPLC and TLC analytical methods to determine radiochemical purity of
Mutin J; Orhon P; Choisnard L; Lassiaz M; Bacot S; Ahmadi M; De Leiris N; Djaileb L; Broisat A; Ghezzi C; Bedouch P; Brunet MD; Leenhardt J
J Pharm Biomed Anal; 2024 Aug; 246():116224. PubMed ID: 38759321
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
17. Retention of [(18)F]fluoride on reversed phase HPLC columns.
Ory D; Van den Brande J; de Groot T; Serdons K; Bex M; Declercq L; Cleeren F; Ooms M; Van Laere K; Verbruggen A; Bormans G
J Pharm Biomed Anal; 2015; 111():209-14. PubMed ID: 25898315
[TBL] [Abstract][Full Text] [Related]
18. On site production of [
Maisto C; Morisco A; de Marino R; Squame E; Porfidia V; D'Ambrosio L; Di Martino D; Gaballo P; Aurilio M; Buonanno M; Esposito A; Raddi M; Lastoria S
EJNMMI Radiopharm Chem; 2021 Oct; 6(1):36. PubMed ID: 34643830
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
20. Optimization and scale up of production of the PSMA imaging agent [
Alexoff D; Choi SR; Ploessl K; Kim D; Zhao R; Zhu L; Kung H
EJNMMI Radiopharm Chem; 2024 Feb; 9(1):15. PubMed ID: 38393404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
